The U.S. Food and Drug Administration approved the clinical trial application of Changchun High-Tech Industry's (SHE:000661) unit, Changchun Jinsai Pharmaceutical, for GenSci143 for injection, according to a Shenzhen bourse filing on Friday.
The Chinese biopharmaceutical product manufacturer will be able to conduct clinical trials in the U.S. to test the drug as a treatment for advanced solid tumors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments